Board of Directors approved financial results for 31 st December,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Concord Drugs Ltd, meeting on 14 Feb 2026, approved standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2025. The statutory auditor, Pundarikashyam and Associates, issued an unqualified limited review report on both sets of results, with no qualifications, emphasis of matter, or adverse comments. Consolidated results include the subsidiary Proton Remedies Pvt Ltd, which contributed Rs 124.83 lakh in revenue and Rs 1.17 lakh in net profit for the nine-month period. Separately, the board reconstituted the Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees with immediate effect. Independent Director Mr. Ramachandra Reddy ceased to hold office upon completing his tenure. The company also confirmed no deviation in the use of funds from the Rs 13.36 crore preferential issue completed on 20 November 2025, and no defaults on loans or debt securities for the quarter.
Routine quarterly results filing with a clean auditor review provides no negative signal for shareholders, though the exit of an independent director and committee reshuffle are governance items worth tracking. The subsidiary Proton Remedies is currently loss-making at the net profit level, which is a small drag on consolidated earnings.